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 Abstract  
Caring for people suffering from COVID-19 is a significant global challenge. Many individuals infected 
have pre-existing conditions that interact to increase symptom severity and mortality risk. To assess the 
interaction of patient comorbidities with COVID-19 we performed a meta-analysis of the published 
global literature, and machine learning predictive analyses using an aggregated COVID-19 global 
dataset. Meta-analysis identified chronic obstructive pulmonary disease (COPD), cerebrovascular 
disease (CEVD), cardiovascular disease (CVD), type 2 diabetes, malignancy, and hypertension as most 
significantly associated with COVID-19 severity. Machine learning classification using novel 
aggregated cohort data found COPD, CVD, CKD, type 2 diabetes, malignancy, hypertension, and 
asthma as the most significant features for classifying deceased versus survived in COVID-19. 
Symptom-comorbidity interaction analysis found the combinations of Pneumonia-Hypertension, 
Pneumonia-Diabetes, and Acute Respiratory Distress Syndrome with Hypertension had the most 
significant effects on mortality. These results highlight patients most at risk of COVID-19 related severe 
morbidity and mortality. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Introduction 
As of the end of May 2020, over 6 million cases of SARS-CoV-2 infection have been confirmed 
globally, and over 3,696,000 deaths attributed to the associated disease, COVID-19.1 Asymptomatic 
human to human spread remains a challenging aspect of the viral containment effort, unlike previous 
pandemic coronaviruses SARS and MERS, which showed co-occurrence of symptoms with 
infectiousness.2 COVID-19 epidemiological data suggests elderly people are most at risk of developing 
severe symptoms,3 although severe symptoms and mortality occur in all age groups. The more 
prominent symptoms include high fever, cough and sputum production, headache, hemoptysis and 
diarrhea, and as the infection worsens, an acute respiratory distress syndrome can develop that requires 
intensive care management. Identifying those most at risk of severe symptoms and death remains a 
research priority to aid early and appropriate allocation of resources and targeted patient management. 
As more population data is released, predictive analytic methods may be able to provide such 
information for patients based on their clinical characteristics. 
Reports are emerging that many of the patients most affected by COVID-19 also present with significant 
comorbidities. A recent study by Richardson et al.4 describing 5,700 confirmed COVID-19 cases 
reported that many of these patients were suffering from hypertension (56.6%), obesity (41.7%) or type 
2 diabetes (33.8%) at the time of their infection; greater than their respective prevalence in the 
population, which suggests a link to SARS-CoV-2 effects on metabolic and vascular systems. This 
indicates that the comorbidities an individual has may provide crucial prognostic information if SARS-
CoV-2 infection co-occurs. There is also data emerging that suggests significant heterogeneity in disease 
presentation. Xu et al.5 described clinical characteristics (including laboratory and chest radiography 
data) from 62 Chinese COVID-19 patients that differed from those described by Guan et al. in another 
Chinese region.6 The reasons for this heterogeneity in presentations remain unclear, but the relative 
incidence of comorbidities (and other clinical features) in different patient cohorts provide one 
explanation. The nature and strength of comorbidity interaction with COVID-19 may also provide 
important clues to the mechanisms of their interaction and how this may be countered.  
To address these issues, we used three approaches to analyze the currently available clinical information. 
Firstly, we conducted a meta-analysis of available retrospective cohort studies of COVID-19 patient data 
that focused on comorbidity and selected clinical features. Secondly, we also obtained and aggregated a 
novel COVID-19 dataset from 4,81,289 patients from across 141 different countries7, and identified 
significant comorbidity associations. Thirdly, we applied machine learning algorithms to this novel 
aggregated data to classify comorbidities with mortality. These three approaches enabled us to 
thoroughly assess the comorbidities and clinical features most significantly associated with mortality in 
COVID-19 patients. 
 
Results 
 
Meta-analysis of published clinical reports of COVID-19 disease 
Initially, our meta-analysis search terms identified a total of 195 relevant articles. From these articles, 
we excluded 96 duplicate references and considered the remaining 99. By careful screening of the title 
and abstract, we excluded 34 articles based on the criteria noted above (e.g., we did not include case 
reports, review reports) and we only considered full-text papers that examined comorbidity and clinical 
symptoms on COVID-19 patients; these are listed in Table 1. Finally, for the remaining articles, we 
 reviewed the full text and removed a further 36 studies because they were either reviews or editorials 
lacking clinical details. Twenty-six articles eventually met the inclusion criteria for our meta-analysis. A 
flow-diagram of literature screening is shown in Figure 1. 
A total of 13,400 COVID-19 patients from twenty-six studies 4-6, 18-40 were thus included in our meta-
analysis. Most of the studies were conducted in China (24), one was from the USA, and another was 
from Italy.  The mean age of the full sample was 54.5 years, with 8,149 (60.81%) males and 39.19% 
females (Table 1). Of these, there were 2,964 patients (22.11%) who developed a severe condition or 
were admitted to the ICU or had died (Table 1). Note that, for calculating the prevalence we considered 
the full data set from all the 26 publications. However, due to lack of information (patients were not 
stratified based on the degree of severity), we considered only 11 publications in the analysis to assess 
the effect of symptoms and comorbidities on COVID-19 disease severity or death. 
The results of our meta-analysis show the dominant symptomology in COVID-19 disease. Fever 
(typically defined by a body temperature above 38.5°C though sometimes not precisely defined) was the 
most prevalent feature (88.26%, 95% CI 81.31, 92.84%) (Table 2). The next most common significant 
symptom was persistent cough (63.68%, 95% CI 57.49, 69.45), followed by excessive fatigue (40.48%, 
95% CI 34.49, 48.77), dyspnea (26.49%, 95% CI 18.50, 36.39), anorexia (21.92%, 95% CI 13.50, 
33.56), myalgia (21.01%, 95% CI 15.50, 27.82), headache (9.84%, 95% CI 7.38, 13.00), diarrhea 
(7.60%, 95% CI 4.89, 11.63) and nausea (6.50%, 95% CI 3.10, 13.10) (as shown in Table 2). 
Hypertension (23.41%, 95% CI 17.63, 30.63) was the most prevalent comorbidity observed among 
COVID-19 patients, followed by diabetes (11.84%, 95% CI 8.27, 18.14), CVD (10.00%, 95% CI 7.68, 
12.93), malignancy (4.09%, 95% CI 3.18, 5.24), cerebrovascular disease (CEVD; 3.23%, 95% CI 2.02, 
5.13), chronic obstructive pulmonary disease (COPD 3.18%, 95% CI: 2.33, 4.34), chronic kidney 
disease (CKD; 2.78%, 95% CI 1.74, 4.41) and chronic liver disease (CLD 2.50%, 95% CI 1.51, 4.11) 
(Table 3); prevalence of smoking was 8.83% (95% CI 4.19, 17.69) (Table 3). Note that prevalence was 
estimated using a random effects model, and significant (𝑝 < 0.05) high heterogeneities were observed 
for the estimates, with 𝐼! ranging from 79 to 99% (see Table 3).  
Table 4 shows the meta-analysis results of the association between symptoms as well as comorbidities in 
severe and non-severe patients from those articles where severity, ICU support requirement or death 
were reported. When clinical symptoms were stratified according to patient severity, higher odds of 
dyspnea (OR= 2.43, 95% CI 1.52, 3.89) were observed in the severe symptom group. Thus, COVID-19 
patients with dyspnea have more than two fold increase in risk of developing severe symptoms. The 
odds of fever (OR= 1.04, 95% CI: 0.85, 1.28), cough (OR 1.12, 95% CI 0.91, 1.38), fatigue (OR 1.14, 
95% CI 0.96, 1.36), anorexia (OR 1.56, 95% CI 0.93, 2.62), myalgia (OR 0.78, 95% CI 0.54, 1.13), 
headache (OR 1.04, 95% CI 0.69, 1.56), diarrhea (OR 1.14, 95% CI 0.81, 1.61) and nausea (OR 0.93, 
95% CI 0.58, 1.47) were also found to be higher in COVID-19 patients with severe symptoms.  
COPD was found to be the comorbidity feature most significantly associated with high disease severity 
since the odds ratio of COPD (OR 4.76, 95% CI 2.69, 8.39) was the highest among all other 
comorbidities and conditions that were considered. The next most significant comorbidity (or condition) 
relating to disease severity was CEVD (OR 4.54, 95% CI 2.29, 8.99) followed by CVD (OR 3.46, 95% 
CI 2.05, 5.87), CKD (OR 3.22, 95% CI 1.70, 6.10), type II diabetes (OR 2.08, 95% CI  1.39, 3.10), 
malignancy (OR 2.04, 95% CI  1.02, 4.07), hypertension (OR 1.81, 95% CI  1.49, 2.20) and smoking 
(OR 1.74, 95% CI  1.25, 2.42).  
 
 Publication bias 
In parallel to the meta-analysis of data, we also conducted an analysis of publication bias for all 
symptoms and comorbidities. Table 4 shows the results of possible publication biases, which were 
assessed using funnel plots and Egger’s testing (for details, see, Supplementary Figure 3). The results of 
the Egger’s test ( 𝑝 > 0.05) suggest that except for the symptom of anorexia, there were no significant 
publication biases seen in the variables analyzed. 
 
Clinical characteristics of patients in aggregated recently generated COVID-19 patient datasets  
 
Following our meta-analysis of the published literature, we also sought to assess recent COVID-19 
clinical case data available from open-source online repositories; this allowed us to apply additional 
novel predictive machine learning methods to COVID-19 data complementing our meta-analysis of the 
published literature. Data were obtained from two different large data repositories and processed as 
detailed in the methods section. Following filtering for case data to include only cases with sufficiently 
detailed clinical information, as well as case mortality information, we obtained a total of 1,143 patient 
cases for analysis. Table 5 displays summary statistics of these 1,143 patients stratified by 
survival/mortality outcomes. The analysis found that of the 1,143 patients, 86.61% had no 
comorbidities, whereas 5.34% and 7.87% of patients had only one or more than one comorbidity, 
respectively. The most common coexisting comorbidities were hypertension (8.66%), diabetes (7.44%), 
cardiovascular disease (3.5%), and kidney disease (1.75%). In contrast, malignancy of any kind (0.87%), 
asthma (0.87%), COPD (0.61%), chronic lung disease (0.61%), cerebrovascular disease (0.44%), 
surgical history (0.26%), neurodegenerative disease (0.17%), infectious disease (0.17%), and liver 
disease (0.17%) were found to be far less likely to co-occur with COVID-19 in this dataset. Analyzing 
this data for clinical symptomatology found that the most common clinical presentation of patients with 
COVID-19 was fever (14.17%) followed by cough (12.42%), pneumonia (6.47%), acute respiratory 
distress symptoms (5.69%), dyspnea (3.06%), fatigue (2.19%), septic shock (1.49%), headache (0.96%), 
myalgia (0.79%), diarrhea (0.61%) and nausea (0.26%). 
 
Table 5 also shows the status of patients who were deceased. The selected 1143 patients included 319 
(27.91%) deceased, of which 32.60% were female and 61.76% were male. The median age of the 
deceased patients was 51 years and IQR of 36 to 66 years. A majority of patients (67.08%) had no 
comorbidities in this dataset. Only 10.97% of patients had one comorbidity, while 21.94% had more 
than one comorbidity. In the deceased patient subgroup, the rate of comorbidities was significantly 
higher than survived patients. The comorbidities most frequently seen in COVID-19 patients that did not 
survive their infection included type 2 diabetes (19.12%), cardiovascular disease (6.27%), and kidney 
disease (4.08%). However, while the other comorbidities we studied (see Table 5) were less frequently 
observed in COVID-19 patients, when they did co-occur, they did so only in patients who had died 
(Table 5). Descriptive analysis of the symptoms in the deceased COVID-19 patients found that the most 
significant symptoms seen in the deceased patients were pneumonia (21.32%), fever (12.85%), cough 
(11.60%), acute respiratory distress symptom (9.72%) and septic shock (4.70%) (Table 5).  
 
 Supervised machine learning identifies the most significant COVID-19 comorbidities   
To predict significant COVID-19 comorbidities, and to compare with our meta-analysis of the published 
literature, we designed and performed a machine learning analysis of our 1,143 patient’s datasets. We 
applied six different machine learning algorithmic approaches (Random Forest, Decision Tree, GBM, 
XGB, SVM and LGBM) to identify the best predictors of COVID-19 patient mortality among the 
comorbidities and symptoms. We achieved a regression accuracy of > 80% in all six approaches to 
comorbidity and mortality; specifically, that was 83% for Decision Tree, 84% for GBM, and 86% for 
XGB, 87% for Random Forest and SVM, and 88% for LGBM. These methods also achieved accuracy 
for symptoms of > 85% in all six approaches, with GBM and LGBM showing 90% accuracy.  Accuracy 
matrices, including precision, recall or sensitivity, f1 score, area under the ROC curve (AUC), and log 
loss values, are shown in Supplementary Table 1 for symptoms data and in Supplementary Table 2 for 
comorbidity data. The coefficient values for the features (symptoms) are given in Supplementary Table 
3, and the features (comorbidities) are given in Supplementary Table 4. Our results indicate that age is 
the most significant predictor of mortality as well as the gender. We compared both results (most 
significant features) for symptoms and comorbidities found from different algorithms and got similar 
predictions. In figure 2 we represent the significance level for symptoms and diseases. After calculating 
the coefficient values for every algorithm, we measured the symptoms and diseases in the same scale by 
quantile normalization and using the average normalized values in Figure 2. The most significant 
symptoms were pneumonia, acute respiratory distress syndrome (ARDS), dyspnea, fever and cough 
(Supplementary Table 3) and the most significant comorbidities found were hypertension, diabetes and 
metabolic diseases, chronic kidney disease, cardiovascular disease, chronic obstructive pulmonary 
disease (COPD), asthma and malignancy in this cohort (Supplementary Table 4).  
Significant pairs of interacting comorbidities and symptoms associated with death in COVID-19 
One of the unique findings of this study is the identification of significant pairs of comorbidities and 
symptoms that are associated with death among COVID-19 patients. For identification of symptom-
comorbidity interactions, we applied the Fisher’s exact testing procedure. The negative logarithm of the 
p-values obtained from the tests are presented in Figure-3. We observed that the symptom-comorbidity 
combination of Pneumonia-Hypertension, Pneumonia-Diabetes and ARDS-Hypertension had the most 
significant effects on mortality in COVID-19 patients (Figure3).  
Taken together, these data provide a comprehensive analysis of the current published literature, as well 
as a novel machine learning classification analysis using recently aggregated data to identify significant 
comorbidities and symptom relationships relating to death from COVID-19 disease.  
Discussion 
The recent and continuing spread of SARS-CoV-2 has vastly outpaced the ability of many public health 
care systems around the world to respond and manage. There are many examples from even advanced 
economies where medical professionals have had to make distressing decisions about prioritization of 
insufficient care resources. This highlights the critical need for fast and accurate classification of those 
patients most at risk of severe disease or fatality to best allocate hospital resources during times of crisis.   
To this end, we have performed a number of analyses to assess how disease outcome is related to a 
range of patient comorbidities and clinical features. Firstly, we investigated published COVID-19 
clinical data using a conventional meta-analysis. We found almost no evidence of publication bias in this 
data, and little grey literature sources of use to our study. This may reflect the current strong imperative 
 to rapidly publish any available studies. Our meta-analysis identified COPD, CEVD, CVD, diabetes, 
malignancy, and hypertension as most significantly associated with COVID-19 severity in the current 
published literature.  
We also obtained and analyzed aggregated COVID-19 patient data (not derived from published clinical 
trials or retrospective studies) using statistical and machine learning methods. We found that patients 
most at risk of dying from COVID-19 had particular comorbidities and patient features, most of which 
were seen in our meta-analysis. Our machine learning analysis of this patient dataset for the 
classification of deceased versus recovered COVID-19 patients identified COPD, CVD, CKD, diabetes, 
malignancy, hypertension, and asthma as most significant. These results provide detailed insights into 
the strength of the relationship between these factors and patients' risk of dying from COVID-19, 
identifying prognostic factors by largely independent means. This may lead to identification of disease 
mechanisms of interest by considering pathways that may be common to these comorbidities. Already 
such considerations have been made with several studies reporting strong evidence for a link between 
SARS-Cov-2 actions and vascular damage.41 Further, given that the angiotensin converting enzyme 
(ACE-2) receptor is used by the virus for entry into host cells, it has been suggested that the already 
strained ACE-2-Ang-(1-7)-Mas in metabolic disorders may result in a respiratory compromise (42). The 
role of upregulation of the ACE-2 receptors by ACE inhibitors and angiotensin II receptor blockers used 
in the management of hypertension, diabetes, and CKD (43) also requires further exploration in 
elucidating the metabolic pathways that underpin the relationship between these co-morbidities and 
increased SARS-Cov-2 related severe morbidity and mortality.  
It is likely that there are many different factors interacting that lead to the co-incidence of COVID-19 
and comorbidities greatly detrimental to patient outcome. We found using machine learning 
classification methods that age and gender are the most significant predictor of COVID-19 mortality. 
Indeed, it is likely that in many cohorts, age is strongly associated with the co-occurrence of significant 
comorbidities as these tend to be age-related diseases. Nevertheless, comorbidities analyzed here such as 
diabetes, hypertension and asthma do occur across age categories, suggesting mortality in COVID-19 is 
impacted by other characteristics yet to be identified; perhaps differences in environment and/or genetic 
predispositions are likely relevant factors for future consideration.     
Mechanistically, the association between lung-related comorbidities such as COPD and COVID-19 
disease severity are an expected outcome of this study. COPD is a chronic lung condition, often caused 
by a patient history of smoking. Patients with COPD present with pulmonary damage and chronic 
breathing difficulty; thus, the co-occurrence of a severe lower respiratory viral infection and pneumonia 
is a significant challenge, particularly in the elderly. In contrast, the association of severe COVID-19 
disease with conditions such as vascular diseases (CVD, CEVD) and diabetes, is perhaps more complex. 
Data are emerging however that suggests SARS-CoV-2 infection is associated with a severe 
inflammatory storm that can result in vascular inflammation, as well as myocarditis. Thus cardio-
vascular and metabolic diseases are likely compounding the impact of COVID-19; perhaps presenting a 
therapeutic opportunity for broad-spectrum anti-inflammatory medications, although the data on 
efficacy remain to be acquired.  
An important consideration remains the limitations of the available data for predictive analyses. 
COVID-19 remains a relatively recent phenomenon, and thus the data may contain biases that cannot as 
yet be circumvented. For example, the majority of data coming from mainland China presents biases 
related to population genetics as well as environmental effects that will not be observed in similar 
 European datasets. Nevertheless, our analysis of this cohort data from 1143 patients comes from 
repository data acquired from across 141 countries; thus, systematic biases of this kind should be 
minimal. Additionally however, there may be unidentified reporting biases in global hospital data due to 
severe under-resourcing and staff shortages in some locations, necessitating priority reporting. Over the 
coming months, more data will become available from more diverse nations and population groups that 
will enable fuller investigation of these issues.  
 
Conclusion 
In summary, we have performed a comprehensive meta-analysis of available published literature, as 
well as a novel machine learning analysis of a separate cohort of COVID-19 patients. We identified 
significant comorbidities and COVID-19 patient symptoms that are important for consideration when 
assessing patient needs; something that remains critical at a time where hospitals are often understaffed 
and under-resourced. Data suggest that the comorbidities most implicated in severe COVID-19 are lung-
related, such as COPD and asthma, as well as vascular-related conditions, such as CVD and CEVD. 
Thus, it is critical that at-risk populations be prioritized in efforts around social isolation and resource 
allocation during this pandemic. As data continue to be accrued, it will become possible to answer 
questions regarding gender and age-related comorbidity relationships including medication history as 
well as population genetics and environmental effects that may be relevant to treatment optimization. 
 
 
Methods 
This study has two parts - i) meta-analysis of previously published literature, and  
    ii) machine learning algorithm based analysis on patient-level cohort data.   
Meta-analysis of published data 
Search strategy and study selection 
The meta-analysis was conducted according to PRISMA (Preferred Reporting Items for Systematic 
Reviews and Meta-analysis) and MOOSE (Meta-analysis of Observational Studies in Epidemiology) 
guidelines.8-10 Potential and relevant studies were extracted by conducting a systematic search of 
databases; from January 1, 2019, to April 20, 2020, in PubMed (Medline), Springer, Web of Science, 
EMBASE, and Cochrane Library databases. This study used keywords for database screening; ‘2019-
nCoV’, ‘2019 novel coronavirus’, ‘COVID-19’, ‘clinical characteristics and symptoms of coronavirus’. 
Databases using comorbidity combinations for all comorbidities studied were also searched, with the 
following structure: “COVID-19 and diabetes”, “COVID-19 and hypertension”, “COVID-19 and 
COPD” and related terms. The list of cited references from selected articles were manually screened to 
identify missing studies. All articles selected for the meta-analysis were written in English and all search 
procedures were independently performed by two investigators (MMA and AT). 
For this study, articles that described the clinical characteristics of COVID-19 patients were included, 
particularly symptoms and comorbidities, along with their prevalence and specific information on the 
distribution of patients on the basis of severity. Key exclusion criteria were: (a) duplicate publications, 
 (b) case reports, reviews, editorials, letters, or (c) studies that failed to provide sufficient information on 
clinical patient characteristics, as judged by the two investigators.  
 
Data extraction for statistical analysis 
The two investigators who performed the literature screening also extracted the data independently from 
the selected studies. Differences in the chosen literature were reconciled by discussion and screening by 
a third investigator (MAM). We extracted the following variables: first author name, year of publication, 
number of patients, age, sex, number of patients suffering severe diseases (note that patients were not 
stratified based on the degree of comorbidity severity or symptom severity), number of non-severe 
patients where these were reported, patient survival, patients needing intensive care unit (ICU) support, 
and the prevalence of multiple symptoms and comorbidities. The definition of ‘severe’ was clearly 
described in some articles, however not all. We maintained the case definitions as defined by the 
original authors. The odds ratios (OR) were calculated to describe the severity of clinical symptoms in 
severe patients compared to non-severe patients. The degree of variability across studies (heterogeneity) 
was assessed by I2 and Cochran's Q test11. Due to the existence of heterogeneity in studies, random-
effects models were utilized to estimate the average effect of variables, along with their precision which 
can provide a more accurate estimate of the 95% confidence intervals (CI).  
 
Statistical analysis and machine learning analysis of novel aggregate clinical data 
Data collection 
We obtained publicly available anonymized clinical data that was derived from both non-hospitalized 
and hospitalized COVID-19 positive patients; patient diagnoses were based on WHO guidelines.12 The 
cases were captured between February 14, 2020, to April 31, 2020. Real-time data was collected from 
open-source COVID-19 data repositories.13,14 The data obtained came from a total of 4,81,289 
individual patient clinical records from 141 countries. 
 
Summary descriptive statistics for this clinical data are shown in Table 5. The clinical attributes 
collected included clinical symptoms and signs, details of any comorbidities, date of admission in the 
hospital, date of confirmation of COVID-19 caseness, date of death or hospital release, details of other 
associated disease outcomes, as well as demographic data; the latter included age, gender, travel history, 
and location (e.g., city, province, and country) of the patient. From these data, we filtered for select 
criteria e.g. patients who are deceased and recovered and released from hospitals. We also excluded 
patients where data relating to their mortality or recovery from infection was not included. The final 
filtered dataset included 1,143 COVID-19 patients with detailed clinical information, of whom 319 were 
reported as deceased and 824 as recovered. 
 
Selection of significant variables   
The focus of this study was to analyze the mortality and survival rates in our filtered 1,143 patient 
datasets and to relate these rates to comorbidity incidences. We, thus considered respondent age 
(continuous), sex (male, female), travel history, and the commonly occurring comorbidities, both 
individually and occurring in multiples. The comorbidities studied included cardiovascular disease 
 (CVD), chronic obstructive pulmonary disease (COPD), cerebrovascular disease (CEVD), chronic 
kidney disease (CKD), chronic lung disease (CLD), neurodegenerative disease, hypertension, diabetes 
(type 2), malignancies, infectious diseases, surgical history, asthma, and liver disease. Additionally, we 
included several clinical symptoms for analysis, including the incidence of fever, cough, pneumonia, 
acute respiratory distress symptoms (ARDS), dyspnea, fatigue, septic shock, headache, myalgia, 
diarrhea, and nausea, in order to predict at an early stage and to identify the relationship of the severity 
or death. We assessed the influence of these variables on the probability of returning a positive diagnosis 
of SARS-CoV-2 infection.  
Statistical analysis 
Continuous variables were summarized by median along with interquartile range (IQR), and compared 
by utilizing the Mann-Whitney U test.15 The frequency of categorical variables was presented in percent 
and compared with a chi-square test.16 Moreover, Fisher's exact test17 was applied to low-frequency 
cells. A two-sided 𝛼 (type-I error) less than 0.05 was considered as a measure of statistical significance. 
All statistical analysis was performed in the R statistical computing environment (version 3.6.1). 
Machine learning algorithms 
In this study, six supervised machine learning algorithms were applied to identify the minimum number 
of symptoms and comorbidities that were predictive of COVID-19 infection. These algorithms included 
Random Forest, Decision Tree, Gradient Boosting Machine (GBM), XGBoost (XGB), Support Vector 
Machine (SVM) and Light Gradient Boosting Machine (LGBM). We extracted the required variables 
from the raw data, and then performed data cleaning and scaling to pre-process the collected data. 
Imputation techniques were used to address the missing (2.2%) age and gender values, in particular, the 
missing age was imputed using random values selected from the age IQR, and gender was imputed 
randomly according to male and female ratios present in the full dataset. Data was randomly split into 
training (80% individuals) and testing (20% individuals) data sets to perform machine learning 
prediction and validation. To measure accuracy, several measures such as precision, recall or sensitivity, 
f1 score, area under the receiver operating characteristic (ROC) curve (AUC), and log loss values were 
employed. After achieving high accuracy with the model training, we extracted the features with the 
highest impact on symptoms and comorbidities classifying a positive COVID-19 infection.  
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Figure 1: Flow diagram of literature search for including studies in meta-analysis 
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Figure 2: Machine learning models predict the important symptoms and comorbidities that are 
associated with the severity or death of COVID-19 patients. The high coefficient values of ML 
model outcomes mean the higher significant association of death. Figure 2A represents the 
significance of symptoms that are linked with death. Figure 2B represents the significance of 
disease comorbidities that are linked with death. 
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Figure 3: Association and impact of combined symptoms and comorbidity interactions in 
COVID-19 deceased patients.
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Table 1: Summary of study characteristics reported in the selected publications 
First Author Year of 
publication 
Country Sample size 
(n) 
Gender Mean/Median 
age (years) 
Severe or death patients 
n (%) 
Reference 
Male 
n (%) 
Female 
n (%) 
Wang et al. 2020 China 138 75 (54.35) 63 (45.65) 56 36 (26.09) 18 
Richardson et al. 2020 USA (New York) 5,700 3437 (60.30) 2263 (39.70) 63 373 (6.54) 4 
Xu et al. 2020 China 62 35 (56.45) 27 (43.55) 41 NR 5 
Guan et al. 2020 China 1,099 640 (58.23) 459 (41.77) 47 173 (15.74) 6 
Guan WJ et al. 2020 China 1,590 904 (56.86) 686 (43.14) 48.9 254 (15.97) 19 
Huang et al. 2020 China 41 30 (73.17) 11 (26.83) 49 13 (31.71) 20 
Guo et al. 2020 China 187 91 (48.66) 96 (51.34) 58.50 NR 21 
Zhou et al. 2020 China 191 119 (62.30) 72 (37.70) 56.0 66 (34.55) 22 
Zhang et al. 2020 China 140 71 (50.71) 69 (49.29) 57 58 (41.43) 23 
Wu et al. 2020 China 80 39 (48.75) 41 (51.25) 46.10 NR 24 
Liu et al. 2020 China 137 61 (44.53) 76 (54.47) 57 NR 25 
Liu J et al. 2020 China 61 31 (50.82) 30 (49.18) 40 17 (27.87) 26 
Chen et al. 2020 China 99 67 (67.68) 32 (32.32) 55.5 NR 27 
Yang et al. 2020 China 52 35 (67.31) 17 (32.69) 59.7 52 (100.00) 28 
Wu C et al. 2020 China 201 128 (63.68) 73 (36.32) 51 53 (26.37) 29 
Jie Li et al. 2020 China 17 9 (52.94) 8 (47.06) 45.1 NR 30 
Liu W et al. 2020 China 78 39 (50.00) 39 (50.00) 38 NR 31 
Mo etal. 2020 China 155 86 (55.48) 69 (44.52) 54 55 (35.48) 32 
Du et al. 2020 China 85 62 (72.94) 23 (27.06) 65.8 NR 33 
Rong-Hui et al. 2020 China 179 97 (54.19) 82 (45.81) 57.6 NR 34 
Feng et al. 2020 China 476 271 (56.93) 205 (43.07) 53 26 (5.46) 35 
Chen et al. 2020 China 274 171 (62.41) 103 (37.59) 62 113 (41.24) 36 
Grasselli et al. 2020 Italy 1,591 1304 (81.96) 287 (18.04) 63 1,591 (100.00) 37 
Deng et al. 2020 China 225 73 (32.44) 152 (67.56) 69 NR 38 
Wang et al. 2020 China 339 166 (48.97) 173 (51.03) 69 65 (19.17) 39 
Chen TL et al. 2020 China 203 108 (53.20) 95 (76.80) 54 19 (9.36) 40 
Total - - 13,400 8149 (60.81) 5206 (39.19) - 2964 (22.11%) - 
 NR=Not Reported 
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Table 2: Prevalence of symptoms in COVID-19 patients in the selected studies 
First Author Year of 
publication 
Sample 
size 
(n) 
Clinical Symptoms  Reference 
Fever 
(%) 
Cough 
(%) 
Fatigue 
 (%) 
Anorexia 
(%) 
Myalgia 
(%) 
Dyspnea 
(%) 
Diarrhea 
(%) 
Nausea 
(%) 
Headache 
(%) 
 
Wang et al. 2020 138 98.55 59.42 69.57 39.86 34.78 31.16 26.09 10.14 6.52 18 
Richardson et al. 2020 5,700 NR NR NR NR NR NR 6.54 NR NR 4 
Xu et al. 2020 62 77.42 80.65 51.61 NR 51.61 NR NR NR 33.87 5 
Guan et al. 2020 1,099 43.04 67.79 38.13 NR NR NR 15.74 5.00 13.65 6 
Guan WJ et al. 2020 1,590 84.97 66.16 36.73 NR NR NR 15.97 5.03 12.89 19 
Huang et al. 2020 41 97.56 75.61 43.90 NR 43.90 53.66 31.71 NR 7.32 20 
Guo et al. 2020 187 NR NR NR NR NR NR NR NR NR 21 
Zhou et al. 2020 191 94.24 79.06 23.04 NR 15.18 NR 34.55 3.66 NR 22 
Zhang et al. 2020 140 78.57 64.29 64.29 12.14 NR NR 41.43 17.14 NR 23 
Wu et al. 2020 80 NR NR NR NR NR NR NR NR NR 24 
Liu et al. 2020 137 81.75 48.18 32.12 NR 32.12 18.98 NR 62.04 9.49 25 
Liu J et al. 2020 61 98.36 63.93 57.38 NR NR 4.92 27.87 8.20 34.43 26 
Chen et al. 2020 99 82.83 81.82 NR NR NR NR NR 1.01 8.08 27 
Yang et al. 2020 52 98.08 28.85 NR NR 3.85 23.08 100.00 NR 1.92 28 
Wu C et al. 2020 201 93.53 81.09 32.34 NR 32.34 39.80 26.37 NR NR 29 
Jie Li et al. 2020 17 70.59 76.47 47.06 NR 23.53 NR NR NR NR 30 
Liu W et al. 2020 78 NR 43.59 NR NR NR NR NR NR NR 31 
Mo etal. 2020 155 81.29 62.58 38.71 16.77 NR 1.29 35.48 1.94 5.16 32 
Du et al. 2020 85 91.76 NR 58.82 56.47 16.47 70.59 NR NR 4.71 33 
Rong-Hui et al. 2020 179 98.88 81.56 39.66 NR 18.99 49.72 NR NR 9.50 34 
Feng et al. 2020 476 81.93 NR 56.51 NR 11.55 NR 5.46 NR NR 35 
Chen et al. 2020 274 90.88 67.52 50.00 24.09 21.90 NR 41.24 8.76 11.31 36 
Grasselli et al. 2020 1,591 NR NR NR NR NR NR 100.00 NR NR 37 
Deng et al. 2020 225 42.22 20.89 13.33 NR 13.33 34.22 NR NR NR 38 
Wang et al. 2020 339 91.74 52.80 39.82 27.73 4.72 40.71 19.17 3.83 3.54 39 
Chen TL et al. 2020 203 89.16 60.10 7.88 2.96 26.60 1.48 9.36 1.48 4.93 40 
Overall prevalence 
(95% CI) 
 88.26 
(81.31, 
92.84) 
63.68 
(57.49, 
69.45) 
40.48 
(34.49, 
48.77) 
21.92 (13.50, 
33.56 ) 
21.01 
(15.50, 
27.82) 
26.49 
(18.50, 
36.39) 
7.60 (4.89, 
11.63) 
6.50 
(3.10, 
13.10) 
9.84 (7.38, 
13.00) 
- 
𝑰𝟐(%)  98 94 94 94 92 93 93 97 87 - 𝒑 for heterogeneity  <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 - 
Note: Meta-analysis for the prevalence was calculated from random-effects model analysis (see, Supplementary Figure 1 for details); NR=Not Reported 
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Table 3: Prevalence of comorbidities in COVID-19 patients in the selected studies   
First Author Year of 
publication 
Sample size 
(n) 
Comorbidities Reference 
Hypertension 
      (%) 
Diabetes 
   (%) 
CVD 
 (%) 
Malignancy 
     (%) 
COPD 
(%) 
CEVD 
(%) 
CKD 
(%) 
CLD 
(%) 
Smoking 
(%) 
 
Wang et al. 2020 138 31.16 10.14 14.49 7.25 2.90 5.07 2.90 2.90 NR 18 
Richardson et al. 2020 5,700 53.09 31.72 14.46 5.61 5.04 NR 7.95 0.19 47.21 4 
Xu et al. 2020 62 8.06 1.61 NR NR 1.61 1.61 1.61 11.29 NR 5 
Guan et al. 2020 1,099 15.01 7.37 2.46 0.91 1.09 1.36 0.73 2.09 14.37 6 
Guan WJ et al. 2020 1,590 16.92 8.18 3.71 8.18 1.51 1.89 16.92 1.51 6.98 19 
Huang et al. 2020 41 14.63 19.51 4.88 2.44 2.44 NR NR 2.44 7.31 20 
Guo et al. 2020 187 32.62 14.97 11.23 NR 2.14 NR 3.21 NR 9.62 21 
Zhou et al. 2020 191 30.37 18.85 7.85 NR NR NR 1.05 NR 5.75 22 
Zhang et al. 2020 140 30.00 12.14 7.14 NR 1.43 NR 1.43 5.71 6.42 23 
Wu et al. 2020 80 NR NR 31.25 5.00 NR NR 1.25 1.25 NR 24 
Liu et al. 2020 137 9.49 10.22 7.30 1.46 1.46 NR NR NR NR 25 
Liu J et al. 2020 61 19.67 8.20 NR NR 8.20 1.64 NR NR 6.55 26 
Chen et al. 2020 99 NR 12.12 40.40 NR 1.01 NR NR NR NR 27 
Yang et al. 2020 52 NR 3.85 7.69 1.92 NR NR NR NR 3.84 28 
Wu C et al. 2020 201 19.40 10.95 3.98 NR 2.49 NR 1.00 3.48 NR 29 
Jie Li et al. 2020 17 5.88 NR NR NR NR NR NR NR 17.64 30 
Liu W et al. 2020 78 10.26 6.41 NR 5.13 2.56 NR NR NR 6.41 31 
Mo etal. 2020 155 23.87 9.68 9.68 4.52 3.23 4.52 3.87 4.52 3.87 32 
Du et al. 2020 85 37.65 22.35 11.76 7.06 2.35 8.24 3.53 5.88 NR 33 
Rong-Hui et al. 2020 179 32.40 18.44 16.20 2.23 NR NR 2.23 NR NR 34 
Feng et al. 2020 476 NR NR NR NR NR NR NR NR 9.24 35 
Chen et al. 2020 274 33.94 17.15 8.76 2.55 6.57 1.46 1.46 4.01 6.93 36 
Grasselli et al. 2020 1,591 31.99 11.31 14.02 5.09 2.64 NR 2.26 1.76 NR 37 
Deng et al. 2020 225 17.78 7.56 5.78 2.67 9.78 NR NR NR NR 38 
Wang et al. 2020 339 40.71 15.93 15.63 4.42 6.19 6.19 3.83 0.59 NR 39 
Chen TL et al. 2020 203 21.18 7.88 7.88 3.45 3.94 4.43 3.94 3.94 NR 40 
Overall prevalence 
(95% CI) 
 23.41 (17.63, 
30.63) 
11.84 (8.27, 
18.14) 
10.00 
(7.68, 
12.93) 
4.09 (3.18, 
5.24) 
3.18 
(2.33, 
4.34) 
3.23 
(2.02, 
5.13) 
2.78 
(1.74, 
4.41) 
2.50 
(1.51, 
4.11) 
8.83 (4.19, 
17.69) 
- 
𝑰𝟐(%)  98 97 94 79 82 79 95 88 99 - 𝒑 for heterogeneity  <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 - 
CVD= Cardiovascular disease; COPD=Chronic obstructive pulmonary disease; CEVD= Cerebrovascular disease; CKD=Chronic Kidney Disease; CLD=Chronic lung disease.	Note: Meta-
analysis for the prevalence was calculated from random-effects model analysis (see, Supplementary Figure 1 for details)
 	 21	
Table 4: Odds ratio representing the severity of comorbidities and symptoms in COVID-19 patients obtained 
from meta-analysis of published data 
Outcomes  Number of Studies Number of Patients Odds ratio 
(95% CI) 
𝑰𝟐 % 
(P value) 
P value of 
Egger’s test 
Comorbidities - - - - - 
        Hypertension 10 2641 1.81 (1.49, 2.20) 0 (0.72) 0.551 
        Diabetes 11 2693 2.08 (1.39, 3.10) 46 (0.05) 0.949 
        CVD 6 1150 3.46 (2.05, 5.87) 32 (0.21) 1.141 
        Malignancy 6 1161 2.04 (1.02, 4.07) 0 (0.67) 0.466 
        COPD 8 2176 4.76 (2.69, 8.39) 0 (0.97) 0.235 
        CEVD 6 2208 4.54 (2.29, 8.99) 16 (0.31) 0.633 
        CKD 8 2539 3.22 (1.70, 6.10) 0 (0.93) 0.593 
        Smoking 6 1920 1.74 (1.25, 2.42) 0 (0.88) 0.916 
Clinical Symptoms -  - - - 
        Fever 11 2693 1.04 (0.85, 1.28) 42 (0.07) 0.479 
        Cough 11 2693 1.12 (0.91, 1.38) 41 (0.09) 0.354 
        Fatigue 10 2641 1.14 (0.96, 1.36) 0 (0.99) 0.183 
        Anorexia 5 1046 1.56 (0.93, 2.62) 62 (0.03) 0.018 
        Myalgia 7 1238 0.78 (0.54, 1.13) 0 (0.68) 0.685 
        Dyspnea 7 989 2.43 (1.52, 3.89) 19 (0.29) 0.774 
        Diarrhea 9 2600 1.14 (0.81, 1.61) 8 (0.37) 0.731 
        Nausea 7 2242 0.93 (0.58, 1.47) 15 (0.31) 0.458 
        Headache 6 1779 1.04 (0.69, 1.56) 11 (0.34) 0.832 
Note: CVD= Cardiovascular disease; COPD=Chronic obstructive pulmonary disease; CEVD= Cerebrovascular disease; CKD=Chronic 
Kidney Disease; CLD= Chronic lung disease; Odds ratio: Meta-Analysis for overall odds ratio (see, Supplementary Figure 2 & 3 for 
details); P value of Egger’s test: Assessing the publication bias (see, Supplementary Figure-4 details) 
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Table 5: Association between patient survival and selected demographic characteristics, comorbidities and 
clinical symptoms. 
Characteristics All Patients, n=1143 
(%) 
 
Patient’s Condition P value 
Dead, n=319 
(%) 
Survived, n=824 
(%) 
 
Age, median (IQR)  51 (36-66)  74 (63-82) 46 (32-53) <0.001 
Gender       <0.001 
     Female 388 (33.95) 104 (32.60) 284 (34.47) - 
     Male 600 (52.49) 197 (61.76) 403 (48.91) - 
     Unknown 155 (13.56) 18 (5.64) 137 (16.63) - 
Travel History 370 (32.37) 80 (25.08) 290 (35.19) 0.001 
Comorbidities     
CVD 21 (1.84) 16 (5.01) 5 (0.61) <0.001 
CEVD 4 (0.35) 4 (1.25) 0 0.005 
CLD 7 (0.61) 3 (0.94) 4 (0.49) 0.406 
Malignancy 9 (0.79) 4 (1.25) 5 (0.61) 0.275 
Diabetes and Metabolic Disease 80 (6.99) 61 (19.12) 19 (2.31) <0.001 
Liver Disease 2 (0.17) 2 (0.63) 0 0.078 
CKD 20 (1.75) 13 (4.08) 7 (0.85) <0.001 
Neurodegenerative Disease 2 (0.17) 2 (0.63) 0 0.078 
Infectious Disease 2 (0.17) 0 2 (0.24) 1.00 
Surgical History 3 (0.26) 1 (0.31) 2 (0.24) 1.00 
COPD 8 (0.69) 6 (1.88) 2 (0.24) 0.007 
Asthma 10 (0.87) 5 (1.57) 5 (0.61) 0.226 
Hypertension 100 (8.74) 74 (23.19) 26 (3.15) <0.001 
Symptoms     
Headache 11 (0.96) 1 (0.31) 10 (1.21) 0.308 
Fever 145 (12.68) 39 (12.22) 106 (12.86) 0.848 
Cough 113 (9.88) 29 (9.09) 84 (10.19) 0.653 
Fatigue 25 (2.19) 8 (2.51) 17 (2.06) 0.814 
Nausea 3 (0.26) 1 (0.31) 2 (0.24) 1.00 
Diarrhea 7 (0.61) 1 (0.31) 6 (0.73) 0.681 
Myalgia 11 (0.96) 3 (0.94) 8 (0.97) 1.00 
Dyspnea 59 (5.16) 48 (15.04) 11 (1.33) <0.001 
Pneumonia 74 (6.47) 66 (20.69) 6 (0.73) <0.001 
ARDS 67 (5.86) 60 (18.81) 7 (0.85) <0.001 
Septic Shock 18 (1.57) 16 (5.02) 2 (0.24) <0.001 
Comorbidity Number    <0.001 
      No Comorbidity 990 (86.61) 214 (67.08) 775 (94.05) - 
      Comorbidity=1 61 (5.34) 35 (10.97) 27 (3.28) - 
      Comorbidity>1 90 (7.87) 70 (21.94) 5 (0.61) - 
Note: CVD= Cardiovascular disease; COPD=Chronic obstructive pulmonary disease; CEVD= Cerebrovascular disease; CKD=Chronic 
Kidney Disease; CLD= Chronic lung disease; ARDS=Acute Respiratory Distress Syndrome 
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A. Fever  B. Cough 
  
C. Fatigue D. Anorexia 
 
 
 
Study
Random effects model
Heterogeneity: I 2 = 98%, 2 = 1.4403, 20
2  = 942.36 (p < 0.01)
Wang et al.             
Xu et al.               
Guan et al.             
Guan WJ et al.          
Huang et al.            
Zhou et al.             
Zhang et al.            
Liu et al.              
Liu et al.              
Chen et al.             
Yang et al.             
Wu et al.               
Jie Li et al.           
Mo etal.                
Du et al.               
Rong-Hui et al.         
Feng et al.             
Chen et al.             
Deng et al.             
Wang et al.             
Chen TL et al.          
Fever
 136
  48
 473
1351
  40
 180
 110
 112
  60
  82
  51
 188
  12
 126
  78
 177
 390
 249
  95
 311
 181
Total
.
 138
  62
1099
1590
  41
 191
 140
 137
  61
  99
  52
 201
  17
 155
  85
 179
 476
 274
 225
 339
 203
Prevalence
88.25
98.55
77.42
43.04
84.97
97.56
94.24
78.57
81.75
98.36
82.83
98.08
93.53
70.59
81.29
91.76
98.88
81.93
90.88
42.22
91.74
89.16
95% C.I.
[81.31; 92.84]
[94.39; 99.64]
[65.40; 86.15]
[40.14; 45.99]
[83.13; 86.64]
[84.61; 99.66]
[89.90; 96.78]
[71.00; 84.59]
[74.39; 87.36]
[89.27; 99.77]
[74.10; 89.05]
[87.57; 99.73]
[89.18; 96.21]
[45.81; 87.20]
[74.37; 86.68]
[83.72; 96.02]
[95.64; 99.72]
[78.22; 85.14]
[86.85; 93.76]
[35.93; 48.77]
[88.30; 94.24]
[84.09; 92.76]
40 50 60 70 80 90
Prevalence of Fever
Study
Random effects model
Heterogeneity: I 2 = 94%, 2 = 0.3029, 19
2  = 305.96 (p < 0.01)
Wang et al.             
Xu et al.               
Guan et al.             
Guan WJ et al.          
Huang et al.            
Zhou et al.             
Zhang et al.            
Liu et al.              
Liu j et al.            
Chen et al.             
Yang et al.             
Wu et al.               
Jie Li et al.           
Liu W et al.            
Mo etal.                
Rong-Hui et al.         
Chen et al.             
Deng et al.             
Wang et al.             
Chen TL et al.          
Cough
  82
  50
 745
1052
  31
 151
  90
  66
  39
  81
  15
 163
  13
  34
  97
 146
 185
  47
 179
 122
Total
.
 138
  62
1099
1590
  41
 191
 140
 137
  61
  99
  52
 201
  17
  78
 155
 179
 274
 225
 339
 203
Prevalence
63.68
59.42
80.65
67.79
66.16
75.61
79.06
64.29
48.18
63.93
81.82
28.85
81.09
76.47
43.59
62.58
81.56
67.52
20.89
52.80
60.10
95% C.I.
[57.49; 69.45]
[51.04; 67.29]
[68.93; 88.67]
[64.97; 70.49]
[63.80; 68.45]
[60.32; 86.34]
[72.71; 84.25]
[56.02; 71.78]
[39.94; 56.52]
[51.25; 74.93]
[72.97; 88.23]
[18.20; 42.48]
[75.08; 85.93]
[51.45; 90.88]
[33.06; 54.73]
[54.71; 69.84]
[75.20; 86.59]
[61.75; 72.80]
[16.07; 26.69]
[47.48; 58.07]
[53.21; 66.61]
20 30 40 50 60 70 80 90
Prevalence of Cough
Study
Random effects model
Heterogeneity: I2 = 94%, 2 = 0.2849, 18
2  = 319.55 (p  < 0.01)
Wang et al.             
Xu et al.               
Guan et al.             
Guan WJ et al.          
Huang et al.            
Zhou et al.             
Zhang et al.            
Liu et al.              
Liu j et al.            
Wu et al.               
Jie Li et al.           
Mo etal.                
Du et al.               
Rong-Hui et al.         
Feng et al.             
Chen et al.             
Deng et al.             
Wang et al.             
Chen TL et al.          
Fatigue
 96
 32
419
584
 18
 44
 90
 44
 35
 65
  8
 60
 50
 71
269
137
 30
135
 16
Total
.
 138
  62
1099
1590
  41
 191
 140
 137
  61
 201
  17
 155
  85
 179
 476
 274
 225
 339
 203
Prevalence
40.48
69.57
51.61
38.13
36.73
43.90
23.04
64.29
32.12
57.38
32.34
47.06
38.71
58.82
39.66
56.51
50.00
13.33
39.82
7.88
95% C.I.
[34.49; 46.77]
[61.40; 76.66]
[39.33; 63.71]
[35.30; 41.04]
[34.39; 39.13]
[29.69; 59.19]
[17.61; 29.54]
[56.02; 71.78]
[24.84; 40.38]
[44.76; 69.10]
[26.23; 39.11]
[25.54; 69.73]
[31.37; 46.60]
[48.12; 68.75]
[32.76; 47.00]
[52.02; 60.90]
[44.11; 55.89]
[ 9.48; 18.43]
[34.74; 45.13]
[ 4.88; 12.48]
10 20 30 40 50 60 70
Prevalence of Fatigue
Study
Random effects model
Heterogeneity: I2 = 94%, 2 = 0.5751, 6
2 = 104.15 (p  < 0.01)
Wang et al.             
Zhang et al.            
Mo etal.                
Du et al.               
Chen et al.             
Wang et al.             
Chen TL et al.          
Anorexia
55
17
26
48
66
94
 6
Total
.
138
140
155
 85
274
339
203
Prevalence
21.92
39.86
12.14
16.77
56.47
24.09
27.73
2.96
95% C.I.
[13.50; 33.56]
[32.03; 48.23]
[ 7.68; 18.67]
[11.68; 23.50]
[45.80; 66.58]
[19.39; 29.50]
[23.22; 32.74]
[ 1.33;  6.42]
10 20 30 40 50 60
Prevalence of Anorexia
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E. Myalgia F. Dyspnea 
  
G. Diarrhea  H. Nausea 
 
 
 
Study
Random effects model
Heterogeneity: I 2 = 92%, 2 = 0.4637, 14
2  = 172.65 (p < 0.01)
Wang et al.             
Xu et al.               
Huang et al.            
Zhou et al.             
Liu et al.              
Yang et al.             
Wu et al.               
Jie Li et al.           
Du et al.               
Rong-Hui et al.         
Feng et al.             
Chen et al.             
Deng et al.             
Wang et al.             
Chen TL et al.          
Myalgia
48
32
18
29
44
 2
65
 4
14
34
55
60
30
16
54
Total
.
138
 62
 41
191
137
 52
201
 17
 85
179
476
274
225
339
203
Prevalence
21.01
34.78
51.61
43.90
15.18
32.12
3.85
32.34
23.53
16.47
18.99
11.55
21.90
13.33
4.72
26.60
95% C.I.
[15.50; 27.82]
[27.31; 43.09]
[39.33; 63.71]
[29.69; 59.19]
[10.76; 21.00]
[24.84; 40.38]
[ 0.96; 14.12]
[26.23; 39.11]
[ 9.12; 48.55]
[10.00; 25.91]
[13.90; 25.41]
[ 8.98; 14.75]
[17.39; 27.18]
[ 9.48; 18.43]
[ 2.91;  7.56]
[20.98; 33.10]
10 20 30 40 50 60
Prevalence of Myalgia
Study
Random effects model
Heterogeneity: I 2 = 93%, 2 = 0.5613, 11
2  = 164.14 (p < 0.01)
Wang et al.             
Huang et al.            
Liu et al.              
Liu j et al.            
Yang et al.             
Wu et al.               
Mo etal.                
Du et al.               
Rong-Hui et al.         
Deng et al.             
Wang et al.             
Chen TL et al.          
Dyspnea
 43
 22
 26
  3
 12
 80
  2
 60
 89
 77
138
  3
Total
.
138
 41
137
 61
 52
201
155
 85
179
225
339
203
Prevalence
26.49
31.16
53.66
18.98
4.92
23.08
39.80
1.29
70.59
49.72
34.22
40.71
1.48
95% C.I.
[18.50; 36.39]
[24.00; 39.35]
[38.53; 68.14]
[13.26; 26.42]
[ 1.59; 14.17]
[13.60; 36.38]
[33.27; 46.72]
[ 0.32;  5.01]
[60.08; 79.28]
[42.45; 57.00]
[28.32; 40.66]
[35.60; 46.02]
[ 0.48;  4.48]
20 40 60
Prevalence of Dyspnea
Study
Random effects model
Heterogeneity: I 2 = 93%, 2 = 0.8183, 16
2  = 228.44 (p < 0.01)
Wang et al.             
Xu et al.               
Guan et al.             
Guan WJ et al.          
Huang et al.            
Zhou et al.             
Zhang et al.            
Liu et al.              
Liu j et al.            
Chen et al.             
Jie Li et al.           
Mo etal.                
Du et al.               
Chen et al.             
Deng et al.             
Wang et al.             
Chen TL et al.          
Diarrhea
14
 3
42
57
 1
 9
18
11
 6
 2
 2
 7
16
77
19
43
10
Total
.
 138
  62
1099
1590
  41
 191
 140
 137
  61
  99
  17
 155
  85
 274
 225
 339
 203
Prevalence
7.60
10.14
4.84
3.82
3.58
2.44
4.71
12.86
8.03
9.84
2.02
11.76
4.52
18.82
28.10
8.44
12.68
4.93
95% C.I.
[ 4.89; 11.63]
[ 6.10; 16.40]
[ 1.57; 13.96]
[ 2.84;  5.13]
[ 2.78;  4.62]
[ 0.34; 15.39]
[ 2.47;  8.81]
[ 8.25; 19.49]
[ 4.50; 13.92]
[ 4.49; 20.22]
[ 0.51;  7.72]
[ 2.96; 36.83]
[ 2.17;  9.17]
[11.86; 28.54]
[23.10; 33.72]
[ 5.45; 12.86]
[ 9.54; 16.67]
[ 2.67;  8.91]
5 10 15 20 25 30 35
Prevalence of Diarrhea
Study
Random effects model
Heterogeneity: I2 = 97%, 2 = 1.7067, 11
2  = 354.93 (p  < 0.01)
Wang et al.             
Guan et al.             
Guan WJ et al.          
Zhou et al.             
Zhang et al.            
Liu et al.              
Liu j et al.            
Chen et al.             
Mo etal.                
Chen et al.             
Wang et al.             
Chen TL et al.          
Nausea
14
55
80
 7
24
85
 5
 1
 3
24
13
 3
Total
.
 138
1099
1590
 191
 140
 137
  61
  99
 155
 274
 339
 203
Prevalence
6.50
10.14
5.00
5.03
3.66
17.14
62.04
8.20
1.01
1.94
8.76
3.83
1.48
95% C.I.
[ 3.10; 13.10]
[ 6.10; 16.40]
[ 3.86;  6.46]
[ 4.06;  6.22]
[ 1.76;  7.49]
[11.76; 24.31]
[53.65; 69.77]
[ 3.45; 18.23]
[ 0.14;  6.82]
[ 0.63;  5.83]
[ 5.94; 12.74]
[ 2.24;  6.49]
[ 0.48;  4.48]
10 20 30 40 50 60
Prevalence of Nausea
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I. Headache J. Hypertension 
  
K. Diabetes  L. CVD 
 
 
Study
Random effects model
Heterogeneity: I 2 = 87%, 2 = 0.2738, 14
2  = 103.80 (p < 0.01)
Wang et al.             
Xu et al.               
Guan et al.             
Guan WJ et al.          
Huang et al.            
Liu et al.              
Liu j et al.            
Chen et al.             
Yang et al.             
Mo etal.                
Du et al.               
Rong-Hui et al.         
Chen et al.             
Wang et al.             
Chen TL et al.          
Headache
  9
 21
150
205
  3
 13
 21
  8
  1
  8
  4
 17
 31
 12
 10
Total
.
 138
  62
1099
1590
  41
 137
  61
  99
  52
 155
  85
 179
 274
 339
 203
Prevalence
9.84
6.52
33.87
13.65
12.89
7.32
9.49
34.43
8.08
1.92
5.16
4.71
9.50
11.31
3.54
4.93
95% C.I.
[ 7.38; 13.00]
[ 3.43; 12.06]
[23.24; 46.43]
[11.74; 15.81]
[11.33; 14.63]
[ 2.38; 20.37]
[ 5.59; 15.66]
[23.64; 47.10]
[ 4.09; 15.33]
[ 0.27; 12.43]
[ 2.60;  9.98]
[ 1.78; 11.88]
[ 5.99; 14.75]
[ 8.07; 15.64]
[ 2.02;  6.13]
[ 2.67;  8.91]
10 20 30 40
Prevalence of Headache
Study
Random effects model
Heterogeneity: I2 = 98%, 2 = 0.6866, 21
2  = 1252.84 (p  < 0.01)
Wang et al.             
Richardson et al.       
Xu et al.               
Guan et al.             
Guan WJ et al.          
Huang et al.            
Guo et al.              
Zhou et al.             
Zhang et al.            
Liu et al.              
Liu j et al.            
Wu et al.               
Jie Li et al.           
Liu W et al.            
Mo etal.                
Du et al.               
Rong-Hui et al.         
Chen et al.             
Grasselli et al.        
Deng et al.             
Wang et al.             
Chen TL et al.          
Hypertension
  43
3026
   5
 165
 269
   6
  61
  58
  42
  13
  12
  39
   1
   8
  37
  32
  58
  93
 509
  40
 138
  43
Total
.
 138
5700
  62
1099
1590
  41
 187
 191
 140
 137
  61
 201
  17
  78
 155
  85
 179
 274
1591
 225
 339
 203
Prevalence
23.41
31.16
53.09
8.06
15.01
16.92
14.63
32.62
30.37
30.00
9.49
19.67
19.40
5.88
10.26
23.87
37.65
32.40
33.94
31.99
17.78
40.71
21.18
95% C.I.
[17.53; 30.53]
[24.00; 39.35]
[51.79; 54.38]
[ 3.40; 17.95]
[13.02; 17.25]
[15.15; 18.84]
[ 6.73; 28.96]
[26.29; 39.66]
[24.26; 37.25]
[22.99; 38.09]
[ 5.59; 15.66]
[11.53; 31.53]
[14.51; 25.46]
[ 0.82; 32.03]
[ 5.21; 19.19]
[17.81; 31.21]
[28.02; 48.36]
[25.95; 39.60]
[28.58; 39.75]
[29.75; 34.33]
[13.32; 23.33]
[35.60; 46.02]
[16.10; 27.34]
10 20 30 40 50
Prevalence of Hypertension
Study
Random effects model
Heterogeneity: I2 = 97%, 2 = 0.7625, 22
2  = 838.27 (p  < 0.01)
Wang et al.             
Richardson et al.       
Xu et al.               
Guan et al.             
Guan WJ et al.          
Huang et al.            
Guo et al.              
Zhou et al.             
Zhang et al.            
Liu et al.              
Liu j et al.            
Chen et al.             
Yang et al.             
Wu et al.               
Liu W et al.            
Mo etal.                
Du et al.               
Rong-Hui et al.         
Chen et al.             
Grasselli et al.        
Deng et al.             
Wang et al.             
Chen TL et al.          
Diabetes
  14
1808
   1
  81
 130
   8
  28
  36
  17
  14
   5
  12
   2
  22
   5
  15
  19
  33
  47
 180
  17
  54
  16
Total
.
 138
5700
  62
1099
1590
  41
 187
 191
 140
 137
  61
  99
  52
 201
  78
 155
  85
 179
 274
1591
 225
 339
 203
Prevalence
11.64
10.14
31.72
1.61
7.37
8.18
19.51
14.97
18.85
12.14
10.22
8.20
12.12
3.85
10.95
6.41
9.68
22.35
18.44
17.15
11.31
7.56
15.93
7.88
95% C.I.
[ 8.27; 16.14]
[ 6.10; 16.40]
[30.52; 32.94]
[ 0.23; 10.57]
[ 5.97;  9.07]
[ 6.93;  9.63]
[10.07; 34.42]
[10.54; 20.83]
[13.91; 25.02]
[ 7.68; 18.67]
[ 6.15; 16.52]
[ 3.45; 18.23]
[ 7.01; 20.14]
[ 0.96; 14.12]
[ 7.32; 16.06]
[ 2.69; 14.49]
[ 5.92; 15.43]
[14.74; 32.41]
[13.41; 24.80]
[13.14; 22.09]
[ 9.85; 12.97]
[ 4.75; 11.82]
[12.41; 20.22]
[ 4.88; 12.48]
5 10 15 20 25 30
Prevalence of Diabetes
Study
Random effects model
Heterogeneity: I 2 = 94%, 2 = 0.3830, 20
2  = 328.46 (p  < 0.01)
Wang et al.             
Richardson et al.       
Guan et al.             
Guan WJ et al.          
Huang et al.            
Guo et al.              
Zhou et al.             
Zhang et al.            
Wu et al.               
Liu et al.              
Chen et al.             
Yang et al.             
Wu et al.               
Mo etal.                
Du et al.               
Rong-Hui et al.         
Chen et al.             
Grasselli et al.        
Deng et al.             
Wang et al.             
Chen TL et al.          
CVD
 20
824
 27
 59
  2
 21
 15
 10
 25
 10
 40
  4
  8
 15
 10
 29
 24
223
 13
 53
 16
Total
.
 138
5700
1099
1590
  41
 187
 191
 140
  80
 137
  99
  52
 201
 155
  85
 179
 274
1591
 225
 339
 203
Prevalence
10.00
14.49
14.46
2.46
3.71
4.88
11.23
7.85
7.14
31.25
7.30
40.40
7.69
3.98
9.68
11.76
16.20
8.76
14.02
5.78
15.63
7.88
95% C.I.
[ 7.68; 12.93]
[ 9.54; 21.40]
[13.57; 15.39]
[ 1.69;  3.56]
[ 2.89;  4.76]
[ 1.22; 17.52]
[ 7.44; 16.61]
[ 4.79; 12.62]
[ 3.89; 12.77]
[22.08; 42.17]
[ 3.97; 13.03]
[31.21; 50.32]
[ 2.92; 18.77]
[ 2.00;  7.76]
[ 5.92; 15.43]
[ 6.45; 20.50]
[11.50; 22.34]
[ 5.94; 12.74]
[12.40; 15.81]
[ 3.38;  9.69]
[12.14; 19.90]
[ 4.88; 12.48]
10 20 30 40 50
Prevalence of CVD
  26
 
M. Malignancy  
 
N. COPD 
 
 
O. CERD P. CKD 
 
 
Study
Random effects model
Heterogeneity: I2 = 79%, 2 = 0.1566, 16
2  = 76.37 (p  < 0.01)
Wang et al.             
Richardson et al.       
Guan et al.             
Guan WJ et al.          
Huang et al.            
Wu et al.               
Liu et al.              
Yang et al.             
Liu W et al.            
Mo etal.                
Du et al.               
Rong-Hui et al.         
Chen et al.             
Grasselli et al.        
Deng et al.             
Wang et al.             
Chen TL et al.          
Malignancy
 10
320
 10
130
  1
  4
  2
  1
  4
  7
  6
  4
  7
 81
  6
 15
  7
Total
.
 138
5700
1099
1590
  41
  80
 137
  52
  78
 155
  85
 179
 274
1591
 225
 339
 203
Prevalence
4.09
7.25
5.61
0.91
8.18
2.44
5.00
1.46
1.92
5.13
4.52
7.06
2.23
2.55
5.09
2.67
4.42
3.45
95% C.I.
[3.18;  5.24]
[3.94; 12.94]
[5.05;  6.24]
[0.49;  1.68]
[6.93;  9.63]
[0.34; 15.39]
[1.89; 12.58]
[0.37;  5.65]
[0.27; 12.43]
[1.94; 12.88]
[2.17;  9.17]
[3.21; 14.83]
[0.84;  5.80]
[1.22;  5.26]
[4.11;  6.29]
[1.20;  5.81]
[2.68;  7.21]
[1.65;  7.05]
2 4 6 8 10 12 14
Prevalence of Malignancy
Study
Random effects model
Heterogeneity: I2 = 82%, 2 = 0.3245, 19
2  = 106.99 (p  < 0.01)
Wang et al.             
Richardson et al.       
Xu et al.               
Guan et al.             
Guan WJ et al.          
Huang et al.            
Guo et al.              
Zhang et al.            
Liu et al.              
Liu j et al.            
Chen et al.             
Wu et al.               
Liu W et al.            
Mo etal.                
Du et al.               
Chen et al.             
Grasselli et al.        
Deng et al.             
Wang et al.             
Chen TL et al.          
COPD
  4
287
  1
 12
 24
  1
  4
  2
  2
  5
  1
  5
  2
  5
  2
 18
 42
 22
 21
  8
Total
.
 138
5700
  62
1099
1590
  41
 187
 140
 137
  61
  99
 201
  78
 155
  85
 274
1591
 225
 339
 203
Prevalence
3.18
2.90
5.04
1.61
1.09
1.51
2.44
2.14
1.43
1.46
8.20
1.01
2.49
2.56
3.23
2.35
6.57
2.64
9.78
6.19
3.94
95% C.I.
[2.33;  4.34]
[1.09;  7.47]
[4.50;  5.63]
[0.23; 10.57]
[0.62;  1.91]
[1.01;  2.24]
[0.34; 15.39]
[0.81;  5.56]
[0.36;  5.53]
[0.37;  5.65]
[3.45; 18.23]
[0.14;  6.82]
[1.04;  5.84]
[0.64;  9.68]
[1.35;  7.51]
[0.59;  8.92]
[4.18; 10.18]
[1.96;  3.55]
[6.52; 14.40]
[4.07;  9.31]
[1.98;  7.68]
5 10 15
Prevalence of COPD
Study
Random effects model
Heterogeneity: I2 = 79%, 2 = 0.4118, 9
2 = 42.32 (p  < 0.01)
Wang et al.             
Xu et al.               
Guan et al.             
Guan WJ et al.          
Liu j et al.            
Mo etal.                
Du et al.               
Chen et al.             
Wang et al.             
Chen TL et al.          
CERD
 7
 1
15
30
 1
 7
 7
 4
21
 9
Total
.
 138
  62
1099
1590
  61
 155
  85
 274
 339
 203
Prevalence
3.23
5.07
1.61
1.36
1.89
1.64
4.52
8.24
1.46
6.19
4.43
95% C.I.
[2.02;  5.13]
[2.44; 10.26]
[0.23; 10.57]
[0.82;  2.25]
[1.32;  2.69]
[0.23; 10.73]
[2.17;  9.17]
[3.98; 16.28]
[0.55;  3.82]
[4.07;  9.31]
[2.32;  8.30]
5 10 15
Prevalence of CERD
Study
Random effects model
Heterogeneity: I2 = 95%, 2 = 0.7596, 16
2  = 344.41 (p  < 0.01)
Wang et al.             
Richardson et al.       
Xu et al.               
Guan et al.             
Guan WJ et al.          
Guo et al.              
Zhou et al.             
Zhang et al.            
Wu et al.               
Wu et al.               
Mo etal.                
Du et al.               
Rong-Hui et al.         
Chen et al.             
Grasselli et al.        
Wang et al.             
Chen TL et al.          
CKD
  4
453
  1
  8
269
  6
  2
  2
  1
  2
  6
  3
  4
  4
 36
 13
  8
Total
.
 138
5700
  62
1099
1590
 187
 191
 140
  80
 201
 155
  85
 179
 274
1591
 339
 203
Prevalence
2.78
2.90
7.95
1.61
0.73
16.92
3.21
1.05
1.43
1.25
1.00
3.87
3.53
2.23
1.46
2.26
3.83
3.94
95% C.I.
[ 1.74;  4.41]
[ 1.09;  7.47]
[ 7.27;  8.68]
[ 0.23; 10.57]
[ 0.36;  1.45]
[15.15; 18.84]
[ 1.45;  6.96]
[ 0.26;  4.09]
[ 0.36;  5.53]
[ 0.18;  8.34]
[ 0.25;  3.89]
[ 1.75;  8.35]
[ 1.14; 10.38]
[ 0.84;  5.80]
[ 0.55;  3.82]
[ 1.64;  3.12]
[ 2.24;  6.49]
[ 1.98;  7.68]
5 10 15
Prevalence of CKD
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Q. CLD R. Smoking 
 
 
 
 
Supplementary Figure 1:  Meta-analysis of prevalence of comorbidities and symptoms COVID-19 fatalities. 
 
 
 
 
 
 
 
Study
Random effects model
Heterogeneity: I 2 = 88%, 2 = 0.8257, 14
2  = 118.20 (p < 0.01)
Wang et al.             
Richardson et al.       
Xu et al.               
Guan et al.             
Guan WJ et al.          
Huang et al.            
Zhang et al.            
Wu et al.               
Wu et al.               
Mo etal.                
Du et al.               
Chen et al.             
Grasselli et al.        
Wang et al.             
Chen TL et al.          
CLD
 4
11
 7
23
24
 1
 8
 1
 7
 7
 5
11
28
 2
 8
Total
.
 138
5700
  62
1099
1590
  41
 140
  80
 201
 155
  85
 274
1591
 339
 203
Prevalence
2.50
2.90
0.19
11.29
2.09
1.51
2.44
5.71
1.25
3.48
4.52
5.88
4.01
1.76
0.59
3.94
95% C.I.
[1.51;  4.11]
[1.09;  7.47]
[0.11;  0.35]
[5.48; 21.84]
[1.39;  3.13]
[1.01;  2.24]
[0.34; 15.39]
[2.88; 11.01]
[0.18;  8.34]
[1.67;  7.12]
[2.17;  9.17]
[2.47; 13.36]
[2.24;  7.10]
[1.22;  2.54]
[0.15;  2.33]
[1.98;  7.68]
5 10 15 20
Prevalence of CLD
Study
Random effects model
Heterogeneity: I2 = 99%, 2 = 2.1578, 13
2  = 1345.04 (p  < 0.01)
Richardson et al.       
Guan et al.             
Guan WJ et al.          
Huang et al.            
Guo et al.              
Zhou et al.             
Zhang et al.            
Liu j et al.            
Yang et al.             
Jie Li et al.           
Liu W et al.            
Mo etal.                
Feng et al.             
Chen et al.             
Smoking
2691
 158
 111
   3
  18
  11
   9
   4
   2
   3
   5
   6
  44
  19
Total
.
5700
1099
1590
  41
 187
 191
 140
  61
  52
  17
  78
 155
 476
 274
Prevalence
8.83
47.21
14.38
6.98
7.32
9.63
5.76
6.43
6.56
3.85
17.65
6.41
3.87
9.24
6.93
95% C.I.
[ 4.19; 17.69]
[45.92; 48.51]
[12.42; 16.58]
[ 5.83;  8.34]
[ 2.38; 20.37]
[ 6.15; 14.76]
[ 3.22; 10.10]
[ 3.38; 11.89]
[ 2.48; 16.21]
[ 0.96; 14.12]
[ 5.80; 42.71]
[ 2.69; 14.49]
[ 1.75;  8.35]
[ 6.95; 12.20]
[ 4.47; 10.61]
10 20 30 40
Prevalence of Smoking
  28
A. Fever  B. Cough 
  
C. Fatigue D. Anorexia 
 
 
 
Study
Total (95% CI)
Prediction interval
Heterogeneity: Tau2 = 0.0459; Chi2 = 17.34, df = 10 (P = 0.07); I2 = 42%
Wang et al.             
Guan et al.             
Huang et al.            
Zhou et al.             
Zhang et al.            
Liu et al.              
Yang et al.             
Mo etal.                
Chen et al.             
Wang et al.             
Chen TL et al.          
Events
 36
 82
 13
 51
 51
 17
 31
 63
104
 56
 17
Total
1917
 136
 473
  40
 180
 110
  60
  51
 126
 249
 311
 181
Experimental
Events
 36
173
 13
 66
 58
 17
 52
 55
113
 65
 19
Total
2693
 138
1099
  41
 191
 140
  61
  52
 155
 274
 339
 203
Control
Weight
100.0%
9.1%
16.3%
4.0%
11.4%
9.8%
5.2%
0.5%
10.4%
14.2%
12.7%
6.5%
MH, Random, 95% CI
1.04 [0.85; 1.28]
 [0.61; 1.79]
1.02 [0.60; 1.75]
1.12 [0.84; 1.50]
1.04 [0.41; 2.64]
0.75 [0.48; 1.16]
1.22 [0.74; 2.02]
1.02 [0.46; 2.26]
0.01 [0.00; 0.25]
1.82 [1.13; 2.94]
1.02 [0.72; 1.45]
0.93 [0.62; 1.38]
1.00 [0.50; 2.00]
Odds Ratio
0.001 0.1 1 10 1000
Odds Ratio
MH, Random, 95% CI
Favours experimental Favours control
Study
Total (95% CI)
Prediction interval
Heterogeneity: Tau2 = 0.0430; Chi2 = 15.20, df = 9 (P = 0.09); I2 = 41%
Wang et al.             
Guan et al.             
Huang et al.            
Zhou et al.             
Zhang et al.            
Liu et al.              
Yang et al.             
Mo etal.                
Chen et al.             
Wang et al.             
Chen TL et al.          
Events
 21
122
 11
 39
 45
 14
 25
 54
 79
 30
 15
Total
1736
  82
 745
  31
 151
  90
  39
  15
  97
 185
 179
 122
Experimental
Events
 36
173
 13
 66
 58
 17
 52
 55
113
 65
 19
Total
2693
 138
1099
  41
 191
 140
  61
  52
 155
 274
 339
 203
Control
Weight
100.0%
8.0%
19.4%
3.9%
11.5%
9.9%
4.9%
0.0%
10.2%
14.4%
11.3%
6.5%
MH, Random, 95% CI
1.12 [0.91; 1.38]
 [0.65; 1.92]
0.98 [0.52; 1.82]
1.05 [0.81; 1.35]
1.18 [0.44; 3.18]
0.66 [0.41; 1.06]
1.41 [0.83; 2.41]
1.45 [0.61; 3.43]
 
2.28 [1.36; 3.83]
1.06 [0.73; 1.55]
0.85 [0.53; 1.37]
1.36 [0.66; 2.78]
Odds Ratio
0.5 1 2
Odds Ratio
MH, Random, 95% CI
Favours experimental Favours control
Study
Total (95% CI)
Prediction interval
Heterogeneity: Tau2 = 0; Chi2 = 1.99, df = 9 (P = 0.99); I2 = 0%
Wang et al.             
Guan et al.             
Huang et al.            
Zhou et al.             
Zhang et al.            
Liu j et al.            
Mo etal.                
Chen et al.             
Wang et al.             
Chen TL et al.          
Events
29
69
 7
15
39
12
27
64
26
 2
Total
1050
  96
 419
  18
  44
  90
  35
  60
 137
 135
  16
Experimental
Events
 36
173
 13
 66
 58
 17
 55
113
 65
 19
Total
2641
 138
1099
  41
 191
 140
  61
 155
 274
 339
 203
Control
Weight
100.0%
8.7%
31.4%
2.2%
6.1%
10.2%
3.6%
8.0%
17.1%
11.4%
1.2%
MH, Random, 95% CI
1.14 [0.96; 1.36]
 [0.93; 1.40]
1.23 [0.69; 2.19]
1.06 [0.78; 1.43]
1.37 [0.43; 4.34]
0.98 [0.49; 1.96]
1.08 [0.63; 1.85]
1.35 [0.55; 3.30]
1.49 [0.81; 2.73]
1.25 [0.83; 1.89]
1.01 [0.61; 1.67]
1.38 [0.29; 6.55]
Odds Ratio
0.2 0.5 1 2 5
Odds Ratio
MH, Random, 95% CI
Favours experimental Favours control
Study
Total (95% CI)
Prediction interval
Heterogeneity: Tau2 = 0.2118; Chi2 = 10.61, df = 4 (P = 0.03); I2 = 62%
Wang et al.             
Zhang et al.            
Mo etal.                
Chen et al.             
Wang et al.             
Events
24
 8
18
31
15
Total
258
 55
 17
 26
 66
 94
Experimental
Events
 36
 58
 55
113
 65
Total
1046
 138
 140
 155
 274
 339
Control
Weight
100.0%
21.7%
14.7%
16.7%
24.4%
22.6%
MH, Random, 95% CI
1.56 [0.93;  2.62]
 [0.29;  8.45]
2.19 [1.14;  4.22]
1.26 [0.46;  3.45]
4.09 [1.67; 10.02]
1.26 [0.74;  2.17]
0.80 [0.43;  1.48]
Odds Ratio
0.1 0.5 1 2 10
Odds Ratio
MH, Random, 95% CI
Favours experimental Favours control
  29
E. Myalgia F. Dyspnea 
 
 
G. Diarrhea  H. Nausea 
 
 
 
Study
Total (95% CI)
Prediction interval
Heterogeneity: Tau2 = 0; Chi2 = 3.14, df = 5 (P = 0.68); I2 = 0%
Wang et al.             
Huang et al.            
Zhou et al.             
Yang et al.             
Chen et al.             
Wang et al.             
Chen TL et al.          
Events
12
 7
 8
 4
21
 1
 2
Total
227
 48
 18
 29
  2
 60
 16
 54
Experimental
Events
 36
 13
 66
 52
113
 65
 19
Total
1238
 138
  41
 191
  52
 274
 339
 203
Control
Weight
100.0%
23.4%
10.1%
17.8%
0.0%
39.5%
3.2%
6.0%
MH, Random, 95% CI
0.78 [0.54; 1.13]
 [0.47; 1.31]
0.94 [0.44; 2.01]
1.37 [0.43; 4.34]
0.72 [0.30; 1.72]
 
0.77 [0.43; 1.37]
0.28 [0.04; 2.17]
0.37 [0.08; 1.65]
Odds Ratio
0.1 0.5 1 2 10
Odds Ratio
MH, Random, 95% CI
Favours experimental Favours control
Study
Total (95% CI)
Prediction interval
Heterogeneity: Tau2 = 0.0664; Chi2 = 6.17, df = 5 (P = 0.29); I2 = 19%
Wang et al.             
Huang et al.            
Liu j et al.            
Yang et al.             
Mo etal.                
Wang et al.             
Chen TL et al.          
Events
23
12
 3
21
 2
38
 1
Total
223
 43
 22
  3
 12
  2
138
  3
Experimental
Events
36
13
17
52
55
65
19
Total
989
138
 41
 61
 52
155
339
203
Control
Weight
100.0%
29.0%
15.8%
2.4%
0.0%
2.3%
47.0%
3.5%
MH, Random, 95% CI
2.43 [1.52;   3.89]
 [0.92;   6.45]
3.26 [1.60;   6.62]
2.58 [0.89;   7.51]
17.80 [0.87; 362.69]
 
9.05 [0.43; 191.95]
1.60 [1.01;   2.54]
4.84 [0.42;  55.91]
Odds Ratio
0.01 0.1 1 10 100
Odds Ratio
MH, Random, 95% CI
Favours experimental Favours control
Study
Total (95% CI)
Prediction interval
Heterogeneity: Tau2 = 0.0224; Chi2 = 8.68, df = 8 (P = 0.37); I2 = 8%
Wang et al.             
Guan et al.             
Zhou et al.             
Zhang et al.            
Liu j et al.            
Mo etal.                
Chen et al.             
Wang et al.             
Chen TL et al.          
Events
 6
10
 2
 9
 1
 5
27
 8
 1
Total
226
 14
 42
  9
 18
  6
  7
 77
 43
 10
Experimental
Events
 36
173
 66
 58
 17
 55
113
 65
 19
Total
2600
 138
1099
 191
 140
  61
 155
 274
 339
 203
Control
Weight
100.0%
8.7%
19.0%
4.4%
11.1%
2.3%
4.1%
32.2%
15.6%
2.6%
MH, Random, 95% CI
1.14 [0.81;  1.61]
 [0.66;  1.96]
2.12 [0.69;  6.54]
1.67 [0.81;  3.47]
0.54 [0.11;  2.68]
1.41 [0.53;  3.78]
0.52 [0.06;  4.76]
4.55 [0.85; 24.21]
0.77 [0.45;  1.30]
0.96 [0.43;  2.18]
1.08 [0.13;  8.96]
Odds Ratio
0.1 0.5 1 2 10
Odds Ratio
MH, Random, 95% CI
Favours experimental Favours control
Study
Total (95% CI)
Prediction interval
Heterogeneity: Tau2 = 0.0589; Chi2 = 7.07, df = 6 (P = 0.31); I2 = 15%
Wang et al.             
Guan et al.             
Zhou et al.             
Zhang et al.            
Liu j et al.            
Chen et al.             
Wang et al.             
Events
 4
12
 3
 5
 2
 8
 1
Total
142
 14
 55
  7
 24
  5
 24
 13
Experimental
Events
 36
173
 66
 58
 17
113
 65
Total
2242
 138
1099
 191
 140
  61
 274
 339
Control
Weight
100.0%
12.3%
31.9%
8.3%
16.1%
5.6%
21.0%
4.7%
MH, Random, 95% CI
0.93 [0.58;  1.47]
 [0.39;  2.20]
1.13 [0.33;  3.84]
1.49 [0.77;  2.89]
1.42 [0.31;  6.54]
0.37 [0.13;  1.05]
1.73 [0.26; 11.25]
0.71 [0.29;  1.72]
0.35 [0.04;  2.75]
Odds Ratio
0.1 0.5 1 2 10
Odds Ratio
MH, Random, 95% CI
Favours experimental Favours control
  30
I. Headache J. Hypertension 
 
 
K. Diabetes  L. CVD 
 
Study
Total (95% CI)
Prediction interval
Heterogeneity: Tau2 = 0.0272; Chi2 = 4.49, df = 4 (P = 0.34); I2 = 11%
Wang et al.             
Guan et al.             
Liu j et al.            
Yang et al.             
Mo etal.                
Chen et al.             
Events
 3
26
 3
 2
 5
11
Total
220
  9
150
 21
  1
  8
 31
Experimental
Events
 36
173
 17
 52
 55
113
Total
1779
 138
1099
  61
  52
 155
 274
Control
Weight
100.0%
7.6%
53.1%
8.6%
0.0%
7.3%
23.4%
MH, Random, 95% CI
1.04 [0.69;  1.56]
 [0.45;  2.41]
1.42 [0.34;  5.96]
1.12 [0.71;  1.77]
0.43 [0.11;  1.65]
 
3.03 [0.70; 13.16]
0.78 [0.36;  1.70]
Odds Ratio
0.1 0.5 1 2 10
Odds Ratio
MH, Random, 95% CI
Favours experimental Favours control
Study
Total (95% CI)
Prediction interval
Heterogeneity: Tau2 = 0; Chi2 = 6.22, df = 9 (P = 0.72); I2 = 0%
Wang et al.             
Guan et al.             
Huang et al.            
Zhou et al.             
Zhang et al.            
Liu j et al.            
Mo etal.                
Chen et al.             
Wang et al.             
Chen TL et al.          
Events
21
41
 2
26
22
 6
22
54
32
 9
Total
637
 43
165
  6
 58
 42
 12
 37
 93
138
 43
Experimental
Events
 36
173
 13
 66
 58
 17
 55
113
 65
 19
Total
2641
 138
1099
  41
 191
 140
  61
 155
 274
 339
 203
Control
Weight
100.0%
7.6%
25.1%
1.1%
10.6%
7.9%
2.4%
7.0%
16.7%
16.5%
5.0%
MH, Random, 95% CI
1.81 [1.49; 2.20]
 [1.44; 2.27]
2.70 [1.33; 5.49]
1.77 [1.20; 2.61]
1.08 [0.17; 6.65]
1.54 [0.85; 2.80]
1.56 [0.78; 3.11]
2.59 [0.73; 9.15]
2.67 [1.28; 5.56]
1.97 [1.22; 3.18]
1.27 [0.79; 2.05]
2.56 [1.07; 6.14]
Odds Ratio
0.2 0.5 1 2 5
Odds Ratio
MH, Random, 95% CI
Favours experimental Favours control
Study
Total (95% CI)
Prediction interval
Heterogeneity: Tau2 = 0.1703; Chi2 = 16.77, df = 9 (P = 0.05); I2 = 46%
Wang et al.             
Guan et al.             
Huang et al.            
Zhou et al.             
Zhang et al.            
Liu j et al.            
Yang et al.             
Mo etal.                
Chen et al.             
Wang et al.             
Chen TL et al.          
Events
 8
28
 1
17
 8
 3
 7
12
24
11
 5
Total
295
 14
 81
  8
 36
 17
  5
  2
 15
 47
 54
 16
Experimental
Events
 36
173
 13
 66
 58
 17
 52
 55
113
 65
 19
Total
2693
 138
1099
  41
 191
 140
  61
  52
 155
 274
 339
 203
Control
Weight
100.0%
8.3%
17.9%
2.9%
13.6%
9.5%
3.8%
0.0%
6.8%
15.4%
13.7%
8.0%
MH, Random, 95% CI
2.08 [1.39;  3.10]
 [0.72;  6.01]
3.78 [1.23; 11.63]
2.83 [1.74;  4.60]
0.31 [0.03;  2.77]
1.69 [0.83;  3.48]
1.26 [0.46;  3.45]
3.88 [0.60; 25.31]
 
7.27 [1.97; 26.88]
1.49 [0.80;  2.76]
1.08 [0.53;  2.21]
4.40 [1.38; 14.01]
Odds Ratio
0.1 0.5 1 2 10
Odds Ratio
MH, Random, 95% CI
Favours experimental Favours control
Study
Total (95% CI)
Prediction interval
Heterogeneity: Tau2 = 0.1131; Chi2 = 5.88, df = 4 (P = 0.21); I2 = 32%
Wang et al.             
Huang et al.            
Mo etal.                
Chen et al.             
Wang et al.             
Chen TL et al.          
Events
 9
 3
14
16
21
 6
Total
130
 20
  2
 15
 24
 53
 16
Experimental
Events
 36
 13
 55
113
 65
 19
Total
1150
 138
  41
 155
 274
 339
 203
Control
Weight
100.0%
20.5%
0.0%
6.0%
22.9%
34.2%
16.5%
MH, Random, 95% CI
3.46 [2.05;   5.87]
 [0.88;  13.63]
2.32 [0.89;   6.05]
 
25.45 [3.26; 198.77]
2.85 [1.18;   6.88]
2.77 [1.50;   5.11]
5.81 [1.90;  17.75]
Odds Ratio
0.01 0.1 1 10 100
Odds Ratio
MH, Random, 95% CI
Favours experimental Favours control
  31
M. Malignancy  N. COPD 
 
O. CERD P. CKD 
 
Study
Total (95% CI)
Prediction interval
Heterogeneity: Tau2 = 0; Chi2 = 2.38, df = 4 (P = 0.67); I2 = 0%
Wang et al.             
Yang et al.             
Mo etal.                
Chen et al.             
Wang et al.             
Chen TL et al.          
Events
 4
 1
 5
 5
 3
 1
Total
47
10
 1
 7
 7
15
 7
Experimental
Events
 36
 52
 55
113
 65
 19
Total
1161
 138
  52
 155
 274
 339
 203
Control
Weight
100.0%
27.2%
0.0%
17.0%
17.3%
28.4%
10.1%
MH, Random, 95% CI
2.04 [1.02;  4.07]
 [0.67;  6.25]
1.89 [0.50;  7.08]
 
4.55 [0.85; 24.21]
3.56 [0.68; 18.68]
1.05 [0.29;  3.84]
1.61 [0.18; 14.12]
Odds Ratio
0.1 0.5 1 2 10
Odds Ratio
MH, Random, 95% CI
Favours experimental Favours control
Study
Total (95% CI)
Prediction interval
Heterogeneity: Tau2 = 0; Chi2 = 1.84, df = 7 (P = 0.97); I2 = 0%
Wang et al.             
Guan et al.             
Huang et al.            
Zhang et al.            
Liu j et al.            
Mo etal.                
Wang et al.             
Chen TL et al.          
Events
 3
 6
 1
 2
 3
 4
11
 1
Total
58
 4
12
 1
 2
 5
 5
21
 8
Experimental
Events
 36
173
 13
 58
 17
 55
 65
 19
Total
2176
 138
1099
  41
 140
  61
 155
 339
 203
Control
Weight
100.0%
6.1%
24.7%
3.0%
3.5%
9.2%
6.6%
40.0%
7.0%
MH, Random, 95% CI
4.76 [2.69;   8.39]
 [2.34;   9.66]
8.50 [0.86;  84.34]
5.35 [1.71;  16.79]
6.33 [0.24; 165.88]
7.05 [0.33; 149.60]
3.88 [0.60;  25.31]
7.27 [0.79;  66.69]
4.64 [1.89;  11.38]
1.38 [0.16;  11.85]
Odds Ratio
0.01 0.1 1 10
Odds Ratio
MH, Random, 95% CI
Favours experimental Favours control
Study
Total (95% CI)
Prediction interval
Heterogeneity: Tau2 = 0.1215; Chi2 = 5.97, df = 5 (P = 0.31); I2 = 16%
Wang et al.             
Guan et al.             
Mo etal.                
Chen et al.             
Wang et al.             
Chen TL et al.          
Events
 6
 4
 7
 4
10
 3
Total
63
 7
15
 7
 4
21
 9
Experimental
Events
 36
173
 55
113
 65
 19
Total
2208
 138
1099
 155
 274
 339
 203
Control
Weight
100.0%
9.2%
25.9%
5.3%
5.1%
36.6%
17.9%
MH, Random, 95% CI
4.54 [2.29;   8.99]
 [1.16;  17.83]
17.00 [1.98; 146.06]
1.95 [0.61;   6.18]
27.16 [1.52; 484.56]
12.81 [0.68; 240.21]
3.83 [1.56;   9.41]
4.84 [1.12;  20.94]
Odds Ratio
0.01 0.1 1 10 100
Odds Ratio
MH, Random, 95% CI
Favours experimental Favours control
Study
Total (95% CI)
Prediction interval
Heterogeneity: Tau2 = 0; Chi2 = 2.49, df = 7 (P = 0.93); I2 = 0%
Wang et al.             
Guan et al.             
Zhou et al.             
Zhang et al.            
Mo etal.                
Chen et al.             
Wang et al.             
Chen TL et al.          
Events
 2
 3
 2
 2
 4
 4
 4
 2
Total
47
 4
 8
 2
 2
 6
 4
13
 8
Experimental
Events
 36
173
 66
 58
 55
113
 65
 19
Total
2539
 138
1099
 191
 140
 155
 274
 339
 203
Control
Weight
100.0%
10.3%
19.7%
4.4%
4.4%
13.7%
4.8%
28.0%
14.7%
MH, Random, 95% CI
3.22 [1.70;   6.10]
 [1.45;   7.15]
2.83 [0.38;  20.86]
3.21 [0.76;  13.56]
9.44 [0.45; 199.42]
7.05 [0.33; 149.60]
3.64 [0.65;  20.49]
12.81 [0.68; 240.21]
1.87 [0.56;   6.27]
3.23 [0.61;  17.12]
Odds Ratio
0.01 0.1 1 10 100
Odds Ratio
MH, Random, 95% CI
Favours experimental Favours control
  32
Q. Smoking  
 
 
 
 
Supplementary Figure 2: Meta-analysis of severity of comorbidities and symptoms in COVID-19 fatalities 
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A. Fever B. Cough C. Fatigue D. Dyspnea 
    
Egger’s test: p= 0.479 Egger’s test: p= 0.354 Egger’s test: p=0.183 Egger’s test: p= 0.774 
    
E. Myalgia F. Anorexia G. Diarrhea H. Nausea 
 
 
 
 
Egger’s test: p= 0.685 Egger’s test: p=0.018 Egger’s test: p= 0.731 Egger’s test: p= 0.458 
    
I. Headache J. Hypertension K. Diabetes L. CVD 
 
  
 
Egger’s test: p= 0.832 Egger’s test: p=0.551 Egger’s test: p= 0.949 Egger’s test: p= 0.141 
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M. Malignancy N. CRED O. Smoking 
  
 
Egger’s test: p=0.466 Egger’s test: p= 0.633 Egger’s test: p=0.916 
   
P. CKD Q. COPD  
 
 
 
Egger’s test: p= 0.593 Egger’s test: p=0.235  
 
Supplementary Figure 3: Assessment of publication bias using funnel plot and Egger’s test 
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         Supplementary Table 1: Accuracy and Evaluation matrices for symptoms data in ML analysis 
Algorithms Accuracy Precision Recall f1 Score AUC Log loss 
Random Forest 0.87 0.89 0.93 0.91 0.83 4.52 
Decision Tree 0.87 0.9 0.93 0.91 0.84 4.37 
XGB 0.89 0.92 0.93 0.92 0.87 3.77 
GBM 0.9 0.93 0.94 0.93 0.88 3.32 
SVM 0.89 0.93 0.91 0.92 0.87 3.92 
Light GBM 0.9 0.94 0.91 0.93 0.89 3.47 
                   Note: XGB= XGBoost; GBM= Gradient Boosting Machine; SVM= Support Vector Machine 
 
         Supplementary Table 2: Accuracy and Evaluation matrices for comorbidity data in ML analysis 
Algorithms Accuracy Precision Recall F1 Score AUC Log loss 
Random Forest 0.87 0.89 0.93 0.91 0.82 4.52 
Decision Tree 0.83 0.85 0.92 0.88 0.76 5.88 
XGB 0.86 0.89 0.92 0.9 0.82 4.83 
GBM 0.84 0.92 0.86 0.89 0.83 5.43 
SVM 0.87 0.91 0.91 0.91 0.84 4.52 
Light GBM 0.88 0.9 0.93 0.92 0.84 4.22 
                Note: XGB= XGBoost; GBM= Gradient Boosting Machine; SVM= Support Vector Machine 
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Supplementary Table 3: Coefficient values for each symptom applying after ML methods 
Algorithms Headache Fever Cough Fatigue Nausea Diarrhea Myalgia Dyspnea Pneumonia ARDS Septic Shock 
Random Forest 0.3 1.89 1.74 0.61 0.18 0.16 0.71 2.94 76.62 4.77 0.69 
Decision Tree 0.28 2.19 1.28 0.9 0.4 0.07 0.68 1.78 4.3 3.66 0.17 
XGB 0 6.67 6.74 3.81 0 0 3.2 13.34 19.7 25.4 1.92 
GBM 0.74 1.6 0.95 0.34 0.07 0.04 0.56 3.07 9.18 7.22 0.8 
SVM 0 24.53 25.3 10.7 10.7 10.7 8.22 21.74 58.67 42.5 5.52 
Light GBM 0 39.77 21.02 0 0 0 0 34.84 95.68 37.7 0.16 
Note: ARDS= Acute respiratory distress syndrome 
 
Supplementary Table 4: Coefficient values for each comorbidity applying after ML methods 
Algorithms Gender Age Hyperten
sion 
CVD CEV
D 
Chronic 
Lung 
Disease 
Malignancy Diabetes 
and 
Metabolic 
Disease  
CLD CKD Neuro
degene
rative 
Diseas
e 
Infectious 
Disease 
Surgical 
History 
COPD Asthma 
Random 
Forest 
2.56 82.9 5.53 1.06 0.27 0.35 0.65 3.67 0.13 1.13 0.27 0.03 0.43 0.82 0.19 
Decision 
Tree 
4.05 85.51 2.57 0.49 0.28 0.45 0.88 3.77 0 0.81 0 0.007 0.55 0.52 0.1 
XGB 9.37 20.77 14.84 5.98 0 2.9 7.37 14.21 0 7 0 0 0 5.77 11.8 
GBM 2.19 77.78 6.48 1.37 0.27 0.23 0.73 7.72 0.09 0.87 0.46 0.05 0.64 1.02 0.09 
SVM 4.07 169.3 34 10.18 23.89 11.66 0 33.58 22.7 29.2 14 15.78 8.34 25.4 24.15 
Light GBM 54.6 1448.16 114.62 0.81 0 0 0 46.38 0 3.53 0 0 0 0 0 
Note: CVD= Cardiovascular disease; COPD=Chronic obstructive pulmonary disease; CEVD= Cerebrovascular disease; CKD=Chronic Kidney Disease; CLD= Chronic lung disease; 
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Supplementary Table 5: Assessing association between comorbidity and symptoms using Fisher’s exact test of 
deceased patients  
Comorbidity Symptoms P value Comorbidity Symptoms P value 
 
 
 
 
 
 
Hypertension 
Headache 0.232  
 
 
 
 
 
CEVD 
Headache 1.00 
Fever 0.423 Fever 0.408 
Cough 0.823 Cough 0.3183 
Fatigue 0.665 Fatigue 1.00 
Nausea or vomiting 0.232 Nausea or vomiting 1.00 
Diarrhea 1.00 Diarrhea 1.00 
Myalgia or 
arthralgia 
1.00 Myalgia or 
arthralgia 
0.03726 
Dyspnea 9.224e-06 Dyspnea 1.00 
Pneumonia 2.2e-16 Pneumonia 0.1905 
ARDS 3.22e-11 ARDS 1.00 
Septic Shock 0.0006291 Septic Shock 0.1868 
 
 
 
 
 
 
Diabetes  
Headache 0.179  
 
 
 
 
 
CLD 
Headache 1.00 
Fever 0.374 Fever 1.00 
Cough 0.444 Cough 0.008005 
Fatigue 0.613 Fatigue 1.00 
Nausea or vomiting 1.00 Nausea or vomiting 1.00 
Diarrhea 0.179 Diarrhea 1.00 
Myalgia or 
arthralgia 
0.447 Myalgia or 
arthralgia 
1.00 
Dyspnea 1.954e-05 Dyspnea 0.02224 
Pneumonia 2.865e-11 Pneumonia 1.00 
ARDS 1.638e-07 ARDS 1.00 
Septic Shock 0.04661 Septic Shock 1.00 
 
 
 
 
 
 
CVD 
Headache 1.00  
 
 
 
 
 
Malignancy 
Headache 1.00 
Fever 0.117 Fever 1.00 
Cough 0.169 Cough 1.00 
Fatigue 1.00 Fatigue 0.08532 
Nausea or vomiting 1.00 Nausea or vomiting 1.00 
Diarrhea 1.00 Diarrhea 1.00 
Myalgia or 
arthralgia 
1.00 Myalgia or 
arthralgia 
1.00 
Dyspnea 0.075 Dyspnea 1.00 
Pneumonia 0.001414 Pneumonia 0.1905 
ARDS 0.01666 ARDS 0.5674 
Septic Shock 0.03891 Septic Shock 0.1868 
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Supplementary Table 5: Assessing association between comorbidity and symptoms using Fisher’s exact test of 
deceased patients (continued…) 
Comorbidity Symptoms P value Comorbidity Symptoms P value 
 
 
 
 
 
 
 
Liver Disease 
Headache 1.00  
 
 
 
 
 
Surgical History 
Headache 1.00 
Fever 1.00 Fever 1.00 
Cough 0.008005 Cough 1.00 
Fatigue 1.00 Fatigue 0.02194 
Nausea or vomiting 1.00 Nausea or vomiting 1.00 
Diarrhea 1.00 Diarrhea 1.00 
Myalgia or 
arthralgia 
1.00 Myalgia or 
arthralgia 
1.00 
Dyspnea 0.02224 Dyspnea 1.00 
Pneumonia 1.00 Pneumonia 1.00 
ARDS 1.00 ARDS 1.00 
Septic Shock 1.00 Septic Shock 1.00 
 
 
 
 
 
 
COPD 
Headache 0.01881  
 
 
 
 
 
Asthma 
Headache 1.00 
Fever 0.5457 Fever 0.4813 
Cough 0.4382 Cough 0.381 
Fatigue 0.1256 Fatigue 1.00 
Nausea or vomiting 1.00 Nausea or vomiting 1.00 
Diarrhea 1.00 Diarrhea 1.00 
Myalgia or 
arthralgia 
1.00 Myalgia or 
arthralgia 
1.00 
Dyspnea 0.2237 Dyspnea 0.1645 
Pneumonia 0.01814 Pneumonia 0.06186 
ARDS 0.08288 ARDS 0.0002047 
Septic Shock 0.268 Septic Shock 0.2281 
 
 
 
 
 
 
Neurodegenerative 
Disease 
Headache 1.00  
 
 
 
 
 
CKD 
Headache 0.05643 
Fever 0.01461 Fever 0.7087 
Cough 0.008005 Cough 1.00 
Fatigue 0.04347 Fatigue 0.3367 
Nausea or vomiting 1.00 Nausea or vomiting 1.00 
Diarrhea 1.00 Diarrhea 1.00 
Myalgia or 
arthralgia 
1.00 Myalgia or 
arthralgia 
1.00 
Dyspnea 0.02224 Dyspnea 0.1642 
Pneumonia 1.00 Pneumonia 1.67e-05 
ARDS 1.00 ARDS 0.0003519 
Septic Shock 1.00 Septic Shock 0.008497 
 
